Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Abrahami et al(1) concludes that the use of dipeptidyl peptidase-4 (DPP-4) inhibitors might be associated with increased risk of cholangiocarcinoma (CCA) and suggests that this is biologically plausible due to the proliferative and anti-apoptotic effects of incretin based drugs on cholangiocytes. However, proliferation or immortalization does not automatically lead to cancers, and there is no evidence that DPP-4 inhibitors are carcinogenic. The duration of exposure (around 2 years) is also short; in a recent epidemic from Japan involving workers exposed to chemicals in printing works, duration of exposure ranged from 7 – 17 years(2).
Incidence of CCA has been increasing in developed countries. An earlier report using 32P postlabelling studies demonstrated DNA-adducts (a biomarker of genotoxin exposure) in samples of CCA from UK(3) but the origin of these environmental genotoxins were never studied. It is possible that DPP-4 inhibitors are acting as promoters (rather than initiators) in a background of cholangiocytes already genetically damaged by an environmental carcinogen. The increasing use of DPP-4 inhibitors warrants urgent investigation into identifying the possible mutagen(s) before we are faced with an epidemic. Abrahmi’s study is a wake-up call and should be taken with the seriousness it deserves.
1. Abrahami D, Douros A, Yin H, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018 Dec 5;363: k4880. doi: 10.1136/bmj.k4880.
2. Kumagai S, Kurumatani N, Arimoto A, Ichihara G. Cholangiocarcinoma among offset colour proof‐printing workers exposed to 1,2‐dichloropropane and/or dichloromethane. Occup Environ Med. 2013;70:508–10.
3. Khan SA, Carmichael PL, Taylor-Robinson SD, Habib N, Thomas HC. DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma. Gut. 2003;52:586-91.
No competing interests
08 December 2018
Senior Consultant Oncology
National Oncology Center, The Royal Hospital, Oman
Senior Consultant Oncology, National Oncology Center, The Royal Hospital, Muscat, Sultanate of Oman